172971-76-5Relevant academic research and scientific papers
Isoniazide-heptamethine indocyanine coupling compound as well as preparation method and application thereof
-
Paragraph 0076; 0081-0083, (2020/05/11)
The invention belongs to the technical field of medicines. The invention relates to an isoniazide-heptamethine indocyanine coupling compound as well as preparation and application of the isoniazide-heptamethine indocyanine coupling compound. According to the invention, a splicing principle is adopted, isoniazidee is connected with a heptamethine indocyanine dye with excellent in-vivo fluorescenceimaging characteristic and tumor targeting function through hydrazone bonds; the novel tumor-targeting isoniazide-heptamethine indocyanine isoniazide coupling compound is designed and obtained, the structural formula of the compound is shown in the formulas (I)-(III), and R1, R2, R3, R4, m and n are shown in the claims and the specification. An in-vitro tumor cell growth inhibition test proves that the compound has a good inhibition effect on prostate tumor cells. A monoamine oxidase inhibitory activity test shows that the compound has a moderate inhibitory effect on monoamine oxidase A, and the inhibitory effect is obviously stronger than that of the isoniazide.
Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents
Guo, Chun,Hou, Zhuang,Mou, Yanhua,Wang, Dun,Yang, Xiaoguang
supporting information, (2020/10/02)
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) has been proved as a target for the treatment of non-small cell lung cancer (NSCLC) with specific gene mutations. However, EGFR-TK inhibitors (EGFR-TKIs) need to enter cancer cells and then competitively interact with the active site of tyrosine kinase receptors to suppress the downstream signaling pathway to inhibit tumor proliferation. In this study, in order to improve the tumor cell targeting ability of EGFR-TKI, EGFR-TKI erlotinib was conjugated with the cancer cell-targeting heptamethine cyanine dyes to form seventeen novel erlotinib-dye conjugates. The efficiency of tumor targeting properties of conjugates against cancer cell growth and EGFR-TK inhibition was evaluated in vitro. The result revealed that most erlotinib-dye conjugates exhibited stronger inhibitory effect on A549, H460, H1299 and MDA-MB-231 cell lines than the parent drug erlotinib. Meanwhile, representative compounds exhibited weak cytotoxicity on human normal mammary epithelial MCF-10A cells. Moreover, the conjugate CE17 also showed ~14-fold higher EGFR-TK inhibition activity (IC50 = 0.124 μM) than erlotinib (IC50 = 5.182 μM) in A549 cell line. Finally, molecular docking analysis verified that the erlotinib moiety of compound CE17 could form hydrogen bond with Met-769 and occupy active cavity of EGFR-TK. Therefore, we believed the integration strategy between heptamethine cyanine dyes and EGFR-TKI will contribute to enhancing the therapeutic effect of EGFR-TKI for NSCLC treatment.
A near-infrared cyanine dye preparation method (by machine translation)
-
, (2019/01/14)
The invention discloses a having excellent light stability of the near-infrared cyanine dye preparation method and use, the dye of the formula I as shown in the structural formula, R1 Hydrogen, methyl, in any one of a carboxyl group; R2 Hydrogen, methyl, alkoxy in any one of; X- Is iodine ion, bromide ion in any one of; n=1 - 5 is any integer. The dye through chemical bonding will be blocked piperidine structure unit introduced into the cycloheptane boeki indole cyanine in the mother's body, such that the resulting dye has good light stability, in the near-infrared region with absorption and emission, and has good photosensitive, photo-thermal characteristic, so that the fabric is colored, near-infrared fluorescence imaging, the photodynamic treatment, heat treating the field have good application prospect. (by machine translation)
Mitochondria-targeted prostate cancer therapy using a near-infrared fluorescence dye–monoamine oxidase A inhibitor conjugate
Lv, Qingzhi,Yang, Xiaoguang,Wang, Menglin,Yang, Jincheng,Qin, Zhilin,Kan, Qiming,Zhang, Haotian,Wang, Yongjun,Wang, Dun,He, Zhonggui
, p. 234 - 242 (2018/05/04)
Prostate cancer (PCa) is the most frequent malignant cancer among men in the USA, leading to substantial morbidity and mortality, while the existing treatments have restricted therapeutic benefits for patients with hormone-refractory PCa (HRPC) and metast
Near infrared active heptacyanine dyes with unique cancer-imaging and cytotoxic properties
Henary, Maged,Pannu, Vaishali,Owens, Eric A.,Aneja, Ritu
, p. 1242 - 1246 (2012/03/26)
Three near-infrared fluorescent heptacarbocyanine dyes have been synthesized using a facile one-pot synthetic approach. The reaction methodology afforded a mixture of three symmetric and unsymmetric heptacyanines containing various N-indolenine substituents, a dicarbocyclic acid (DA), a monoester (ME), and a diester (DE). These compounds were isolated, purified, characterized and biologically investigated for tumor cell cytotoxicity and uptake selectivity. Using cell viability and in vitro proliferation assays, we found that the esterified dyes (monoester, ME and diester, DE) were selectively cytotoxic to cancer cells and spared normal fibroblast cells. Additionally, confocal fluorescence imaging confirmed selective uptake of these dyes in cancer cells, thus suggesting tumor cell targeting.
